Makoto Ueno
A5050530209- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Axon Guidance and Neuronal Signaling
- Genetic factors in colorectal cancer
- Pediatric Hepatobiliary Diseases and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatitis Pathology and Treatment
- Neuroblastoma Research and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- Biomarkers in Disease Mechanisms
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Oral and gingival health research
- Ubiquitin and proteasome pathways
- Bioinformatics and Genomic Networks
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Kanagawa Cancer Center
2016-2025
Kanagawa Prefectural Hospital Organization
2016-2025
Tokushima Bunri University
1990-2024
University of Occupational and Environmental Health Japan
2024
Mitsubishi Tanabe Pharma Corporation
2017-2018
Mitsubishi Group (Japan)
2017-2018
Mitsubishi Chemical (Japan)
2018
Shizuoka Cancer Center
2017
Nagano Red Cross Hospital
2008-2013
Novartis (Japan)
2012
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; 1b) studies. Eligible aged ≥18 years both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, no prior immunotherapy....
Purpose: Patients with pancreatic neuroendocrine neoplasm grade-3 (PanNEN-G3) show variable responses to platinum-based chemotherapy. Recent studies indicated that PanNEN-G3 includes well-differentiated tumor G3 (NET-G3). Here, we examined the clinicopathologic and molecular features of assessed responsiveness chemotherapy survival.Experimental Design: A total 100 patients were collected from 31 institutions, after central review characteristics each histologic subtype [NET-G3 vs. carcinoma...
Clinical Practice Guidelines for Pancreatic Cancer was first published in 2006 by the Japan Pancreas Society, and revised 2009, 2013, 2016, 2019. In July 2022, newly Japanese.For this revision, we developed an entirely new guideline according to Minds Manual Guideline Development 2020, which includes concepts of GRADE-Grading Recommendations Assessment, Development, Evaluation, enable a better understanding current guidelines. Patients public were actively involved both development...
Patients with biliary tract cancer (BTC) have poor prognosis few treatment options. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain transforming growth factor (TGF)-βRII receptor (a TGF-β 'trap') fused to human IgG1 antibody blocking programmed death ligand 1 (PD-L1), has shown clinical efficacy in multiple solid tumors.In this phase I, open-label trial expansion cohort, Asian patients BTC whose disease progressed after first-line...
4079 Background: Antitumor activity with pembro, an anti–PD-1 antibody, has been observed in patients (pts) advanced/metastatic biliary tract cancers (BTC), who have limited treatment options. We present follow-up data from pts advanced BTC treated pembro the KN158 (NCT02628067; phase 2) and KN028 (NCT02054806; 1) studies. Methods: Eligible ≥18 y KN158/KN028 cohorts had histologically/cytologically confirmed incurable that progressed after/failed any number of prior standard regimens,...
387 Background: This Phase 1 study (NCT01938612) evaluated D (anti-PD-L1 mAb) and T (anti-CTLA-4 in Asian pts, whom optimal dosing of is undetermined. No dose-limiting toxicities were observed, durable responses seen a dose escalation phase evaluating various doses regimens Japanese pts (Iguchi, ASCO 2015). The was subsequently expanded to larger cohorts with advanced solid tumors including BTC. Methods: Two selected for the expansion phase: monotherapy (10 mg/kg q2w) D+T (D 20 + 1.0 q4w)....
The incidence of pancreatic cancer (PC) continues to increase in the world, while most patients are diagnosed with advanced stages and survive <12 months. This poor prognosis is attributable difficulty early detection. Here we developed evaluated a multivariate index composed plasma free amino acids (PFAAs) for detection PC.We conducted cross-sectional study multi-institutions Japan. Fasting samples from PC (n = 360), chronic pancreatitis (CP) 28), healthy control (HC) subjects 8372) without...
Abstract Background Biliary tract cancer (BTC) has a poor prognosis and lacks standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast receptor (FGFR) 4, platelet-derived (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a known inhibitor of VEGF receptors 1–3, FGFRs 1–4, PDGFR-α) was evaluated for treatment Methods In this single-arm, multicenter, open-label, phase 2 study, patients with BTC received 24 mg orally once daily 28-day cycles. The primary...
Etoposide plus cisplatin (EP) and irinotecan (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC).To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) patients with NEC the digestive system.This open-label phase 3 randomized clinical trial enrolled chemotherapy-naive aged 20 to 75 years who had recurrent unresectable (according 2010 World Health Organization classification system) arising from gastrointestinal...
Trastuzumab deruxtecan (DS-8201) is an antibody–drug conjugate composed of a humanized monoclonal anti-HER2 antibody, cleavable tetrapeptide-based linker and potent topoisomerase I inhibitor. The drug's efficacy has been proven in HER2-positive breast gastric cancers. rate HER2 positivity biliary tract cancer (BTC) reported to be 5–20%, case reports clinical trials have suggested that inhibitors might active BTC. Here we describe the rationale design phase II HERB trial will evaluate safety...
We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC).Patients untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was primary endpoint. The major secondary end-points included progression-free (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, adverse events. sample size...
Agents targeting the programmed cell death-1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this I study evaluated safety, tolerability, and antitumor durvalumab monotherapy, plus tremelimumab (an anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody) combination therapy, in patients from Asia with biliary tract cancer (BTC), esophageal squamous carcinoma (ESCC), or head neck (HNSCC).Patients advanced BTC, ESCC,...